Company intelligence / Profile preview
Fast Forward Pharmaceuticals BV
Netherlandsorpha.net ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Fast Forward Pharmaceuticals BV is developing anti-CD40 monoclonal antibody therapies targeting chronic inflammatory and autoimmune diseases. Its lead candidate, FFP-104, has reached Phase II clinical trials for liver cirrhosis and primary biliary cirrhosis. Additional programs target Crohn's disease and graft rejection with preclinical or early-stage assets[1][2][4].
- Therapeutic areas
- GastroenterologyImmunology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Fast Forward Pharmaceuticals BV.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fast Forward Pharmaceuticals BV.